Compare Stocks

→ Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$1.70 -10.5%	$1.67	$0.77 ▼ $14.00	$6.89M	1.49	5.19 million shs	439,648 shs
MATN Mateon Therapeutics	$0.04	$0.04	$0.13 ▼ $0.38	$3.25M	1.33	338,444 shs	8,356 shs
NVUS Novus Therapeutics	$2.02 +8.6%	$13.23	$4.50 ▼ $27.32	$2.90M	2.07	78,851 shs	313,628 shs
SLRX Salarius Pharmaceuticals	$0.50 -2.0%	$0.56	$0.43 ▼ $2.31	$2.16M	1.01	99,394 shs	18,069 shs
UMRX Cogent Biosciences	$6.96 -2.2%	$10.50	$0.29 ▼ $3.72	$295.58M	3.93	1.22 million shs	1.21 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	-1.55%	-27.20%	+11.76%	+49.89%	-76.62%
MATN Mateon Therapeutics	0.00%	-3.90%	+7.50%	+9.44%	-1.50%
NVUS Novus Therapeutics	+8.60%	+19.53%	+0.50%	+16.09%	-23.77%
SLRX Salarius Pharmaceuticals	+3.42%	+2.00%	-17.74%	-5.52%	-70.18%
UMRX Cogent Biosciences	+6.11%	+9.54%	+11.42%	+51.49%	-36.65%

Exposed: 10 CENT Crypto to Explode April 20th? (Ad)

Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin

Click For My #1 FREE Crypto for 2024

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADIL Adial Pharmaceuticals	0.7732 of 5 stars	0.0	5.0	0.0	0.0	2.5	0.8	0.6
MATN Mateon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A
MATN Mateon Therapeutics	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A
SLRX Salarius Pharmaceuticals	2.00	Hold	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$2.46 per share	N/A
MATN Mateon Therapeutics	N/A	N/A	N/A	N/A	$0.20 per share	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	$13.13 per share	N/A
SLRX Salarius Pharmaceuticals	$1.84M	1.17	N/A	N/A	$1.34 per share	0.37
UMRX Cogent Biosciences	$22.50M	13.14	N/A	N/A	$1.04 per share	6.69

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$5.12M	-$5.72	N/A	N/A	N/A	N/A	-250.52%	-183.24%	5/10/2024 (Estimated)
MATN Mateon Therapeutics	-$6.64M	N/A	0.00	N/A	N/A	N/A	-64.66%	-42.92%	N/A
NVUS Novus Therapeutics	-$16.01M	-$21.58	N/A	N/A	N/A	N/A	-133.49%	-30.52%	N/A
SLRX Salarius Pharmaceuticals	-$12.54M	-$4.53	N/A	N/A	N/A	N/A	-197.96%	-135.23%	5/9/2024 (Estimated)
UMRX Cogent Biosciences	-$31.83M	-$1.04	N/A	N/A	N/A	-96.84%	-87.78%	-52.14%	N/A

Latest NVUS, SLRX, UMRX, ADIL, and MATN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/22/2024	Q4 2023	SLRX Salarius Pharmaceuticals	-$1.01	-$0.22	+$0.79	-$0.22	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MATN Mateon Therapeutics	N/A	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	N/A
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	4.90	4.90
MATN Mateon Therapeutics	N/A	0.17	0.17
NVUS Novus Therapeutics	N/A	18.78	18.78
SLRX Salarius Pharmaceuticals	N/A	5.02	5.02
UMRX Cogent Biosciences	0.18	2.90	2.90

Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
MATN Mateon Therapeutics	0.07%
NVUS Novus Therapeutics	N/A
SLRX Salarius Pharmaceuticals	11.88%
UMRX Cogent Biosciences	26.39%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	14.47%
MATN Mateon Therapeutics	39.22%
NVUS Novus Therapeutics	2.20%
SLRX Salarius Pharmaceuticals	3.50%
UMRX Cogent Biosciences	31.50%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	16	4.05 million	3.47 million	No Data
MATN Mateon Therapeutics	13	90.24 million	N/A	Not Optionable
NVUS Novus Therapeutics	7	1.44 million	N/A	Not Optionable
SLRX Salarius Pharmaceuticals	2	4.31 million	4.16 million	Not Optionable
UMRX Cogent Biosciences	72	42.47 million	N/A	Not Optionable

NVUS, SLRX, UMRX, ADIL, and MATN Headlines

Source	Headline
	Analysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT) markets.businessinsider.com - February 26 at 5:33 PM
	Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA) markets.businessinsider.com - February 26 at 8:53 AM
	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results markets.businessinsider.com - February 26 at 8:53 AM
	Buy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside Potential markets.businessinsider.com - February 15 at 8:43 AM
	Cogent Biosciences Stock Soars After $225M Private Placement marketwatch.com - February 14 at 10:02 AM
	Cogent Biosciences announces oversubscribed $225M private placement msn.com - February 14 at 10:02 AM
	Buy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug Prospects markets.businessinsider.com - February 9 at 2:23 AM
	Citi starts Cogent Biosciences at buy, cites GI tumor drug potential msn.com - February 8 at 4:22 PM
	Buy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT Trial markets.businessinsider.com - December 15 at 7:55 PM
	Maintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for Bezuclastinib markets.businessinsider.com - December 13 at 5:33 PM
	Dow Surges 100 Points; Cogent Biosciences Shares Plunge markets.businessinsider.com - December 11 at 12:21 PM
	Cogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis Treatment markets.businessinsider.com - December 11 at 12:21 PM
	Cogent Reports Positive Data From Phase 2 APEX Trial Of Bezuclastinib In Systemic Mastocytosis markets.businessinsider.com - December 11 at 10:08 AM
	Cogent slumps after mid-stage data for rare disorder therapy msn.com - December 11 at 10:08 AM
	Potential Upside for Cogent Biosciences Due to Imminent Data Readout for Bezuclastinib and Underpriced Shares markets.businessinsider.com - November 21 at 9:11 AM
	Promising Clinical Trials and Strong Financial Position Justify Buy Rating for Cogent Biosciences markets.businessinsider.com - November 14 at 8:40 AM
	Promising Clinical Trials and Strong Financial Position Support Buy Rating for Cogent Biosciences markets.businessinsider.com - November 4 at 5:21 PM
	Promising Market Potential for Cogent Biosciences’ Bezuclastinib Spurs Buy Rating markets.businessinsider.com - October 28 at 7:55 AM
	Analyst Expectations for Cogent Biosciences's Future benzinga.com - August 30 at 8:53 AM
	Cogent Biosciences Is Beginning To Differentiate Its KIT Inhibitor msn.com - August 15 at 5:40 PM
	LifeSci Capital Remains a Buy on Cogent Biosciences (COGT) markets.businessinsider.com - August 8 at 3:59 PM
	Does Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect? msn.com - July 11 at 1:47 PM
	Cogent Biosciences Shares Rise on Fairmount Funds Management's Stake Acquisition marketwatch.com - June 13 at 11:04 PM
	9 Analysts Have This to Say About Cogent Biosciences markets.businessinsider.com - June 12 at 4:10 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
5 Top-Rated Dividend Stocks With Double-Digit Upside
March 25, 2024 11:19 AM
View 5 Top-Rated Dividend Stocks With Double-Digit Upside
eBay Steadily Climbs as Collectors Drive Growth
March 25, 2024 6:29 AM
View eBay Steadily Climbs as Collectors Drive Growth

All Headlines

Company Descriptions

Adial Pharmaceuticals

NASDAQ:ADIL

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Mateon Therapeutics

OTCMKTS:MATN

Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.

Novus Therapeutics

NASDAQ:NVUS

Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

Salarius Pharmaceuticals

NASDAQ:SLRX

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.

Cogent Biosciences

NASDAQ:UMRX

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial